| 1 | Antidepressants in the acute treatment of post-traumatic stress disorder in adults: a systematic review and meta-analysis | 1.2 | 11 | Citations (PDF) |
| 2 | Novel multi-modal methodology to investigate placebo response in major depressive disorder | 4.5 | 0 | Citations (PDF) |
| 3 | A novel artificial intelligence-based methodology to predict non-specific response to treatment | 3.1 | 1 | Citations (PDF) |
| 4 | Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder | 6.6 | 2 | Citations (PDF) |
| 5 | Effect of augmentation with aripiprazole or augmentation with repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine extended release/duloxetine on cognition: A comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) | 4.5 | 0 | Citations (PDF) |
| 6 | Brain ventricle and choroid plexus morphology as predictor of treatment response in major depression: Findings from the EMBARC study | 2.4 | 11 | Citations (PDF) |
| 7 | Dysregulated inflammatory physiology and cognitive impairment in individuals with depression exhibiting a pro- inflammatory phenotype and receiving omega-3 polyunsaturated fatty acids | 2.7 | 0 | Citations (PDF) |
| 8 | Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial | 7.8 | 33 | Citations (PDF) |
| 9 | Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study | 5.3 | 26 | Citations (PDF) |
| 10 | Using Drift Diffusion and RL Models to Disentangle Effects of Depression On Decision-Making vs. Learning in the Probabilistic Reward Task | 1.9 | 4 | Citations (PDF) |
| 11 | EEG measures of brain arousal in relation to symptom improvement in patients with major depressive disorder: Results from a randomized placebo-controlled clinical trial | 3.1 | 2 | Citations (PDF) |
| 12 | Inflammatory biomarker findings from a randomized controlled trial of heated yoga for depression | 1.6 | 2 | Citations (PDF) |
| 13 | The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents | 53.0 | 96 | Citations (PDF) |
| 14 | Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators | 5.3 | 21 | Citations (PDF) |
| 15 | Ages at menarche and menopause, hormone therapy, and the risk of depression | 2.6 | 30 | Citations (PDF) |
| 16 | Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study | 8.8 | 46 | Citations (PDF) |
| 17 | Esmethadone-HCl (REL-1017): a promising rapid antidepressant | 2.7 | 25 | Citations (PDF) |
| 18 | How should we design future mechanistic and/or efficacy clinical trials? | 5.3 | 14 | Citations (PDF) |
| 19 | Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo | 5.2 | 9 | Citations (PDF) |
| 20 | Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial | 2.4 | 9 | Citations (PDF) |
| 21 | A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence | 3.1 | 6 | Citations (PDF) |
| 22 | Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting | 5.2 | 9 | Citations (PDF) |
| 23 | Suppression and acceptance in unipolar depression: Short‐term and long‐term effects on emotional responding | 5.2 | 1 | Citations (PDF) |
| 24 | Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial | 5.4 | 22 | Citations (PDF) |
| 25 | A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression | 4.5 | 20 | Citations (PDF) |
| 26 | A multi-pronged investigation of option generation using depression, PET and modafinilBrain, 2022, 145, 1854-1865 | 8.4 | 8 | Citations (PDF) |
| 27 | The United States index of socioeconomic deprivation for individuals (USiDep) | 0.4 | 4 | Citations (PDF) |
| 28 | Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design | 1.7 | 2 | Citations (PDF) |
| 29 | Bullying, Psychological, and Physical Trauma During Early Life Increase Risk of Major Depressive Disorder in Adulthood: A Nationwide Community Sample of Korean Adults | 2.4 | 8 | Citations (PDF) |
| 30 | Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response | 5.4 | 31 | Citations (PDF) |
| 31 | Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial | 2.9 | 5 | Citations (PDF) |
| 32 | Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis | 4.5 | 23 | Citations (PDF) |
| 33 | Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study | 5.4 | 28 | Citations (PDF) |
| 34 | Diminished frontal pole size and functional connectivity in young adults with high suicidality | 4.5 | 16 | Citations (PDF) |
| 35 | Use of Staging Models for Treatment-Resistant Depression Is Not Helpful in Predicting Nonresponse to Acute Intravenous Ketamine Treatment | 1.7 | 2 | Citations (PDF) |
| 36 | Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder | 0.0 | 0 | Citations (PDF) |
| 37 | Relationships among subclinical psychotic symptoms in young adults over time | 3.1 | 1 | Citations (PDF) |
| 38 | The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder | 2.6 | 3 | Citations (PDF) |
| 39 | Constricted semantic relations in acute depression | 4.5 | 3 | Citations (PDF) |
| 40 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine | 2.7 | 7 | Citations (PDF) |
| 41 | Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors | 4.2 | 24 | Citations (PDF) |
| 42 | International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators | 7.8 | 67 | Citations (PDF) |
| 43 | Early psychiatric referral after attempted suicide helps prevent suicide reattempts: A longitudinal national cohort study in South Korea | 2.4 | 3 | Citations (PDF) |
| 44 | Associations Between Genetic Risk for Adult Suicide Attempt and Suicidal Behaviors in Young Children in the US | 12.4 | 29 | Citations (PDF) |
| 45 | A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? | 4.2 | 72 | Citations (PDF) |
| 46 | Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder | 1.2 | 10 | Citations (PDF) |
| 47 | Risk Factors for Depression in Adolescents With ADHD: The Impact of Cognitive Biases and Stress | 2.8 | 18 | Citations (PDF) |
| 48 | Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study | 4.0 | 11 | Citations (PDF) |
| 49 | Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation | 2.7 | 54 | Citations (PDF) |
| 50 | Altered temporal, but intact spatial, features of transient network dynamics in psychosis | 7.8 | 25 | Citations (PDF) |
| 51 | Predictive inflammatory biomarkers for change in suicidal ideation in major depressive disorder and panic disorder: A 12-week follow-up study | 2.9 | 30 | Citations (PDF) |
| 52 | Anxious attachment is associated with heightened responsivity of a parietofrontal cortical network that monitors peri-personal space | 3.3 | 22 | Citations (PDF) |
| 53 | Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder | 4.5 | 9 | Citations (PDF) |
| 54 | Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder | 1.7 | 16 | Citations (PDF) |
| 55 | Increased risk of depression before and after unilateral or bilateral oophorectomy: A self-controlled case series study using a nationwide cohort in South Korea | 4.5 | 3 | Citations (PDF) |
| 56 | Relationship between cannabis use and psychotic experiences in college students | 2.3 | 16 | Citations (PDF) |
| 57 | Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder | 3.0 | 10 | Citations (PDF) |
| 58 | Obsessive Thought, Compulsive Behavior, and Their Associations With Suicide Ideation and Attempts and Major Depressive Disorder | 1.0 | 3 | Citations (PDF) |
| 59 | The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study | 1.0 | 28 | Citations (PDF) |
| 60 | Moderators of a resiliency group intervention for frontline clinicians during the COVID-19 pandemic | 4.5 | 8 | Citations (PDF) |
| 61 | Association of smartphone overuse with depression, anxiety, and other addictive behaviors: A nationwide community sample of Korean adults | 3.1 | 21 | Citations (PDF) |
| 62 | Increased metabolic variability is associated with newly diagnosed depression: A nationwide cohort study | 4.5 | 10 | Citations (PDF) |
| 63 | A Patient With Electroconvulsive Therapy–resistant Major Depressive Disorder With a Full Response to Heated Yoga: A Case Report | 0.6 | 3 | Citations (PDF) |
| 64 | Associations Between Smoking, Alcohol Consumption, Physical Activity and Depression in Middle-Aged Premenopausal and Postmenopausal Women | 2.4 | 19 | Citations (PDF) |
| 65 | High Bodyweight Variability Increases Depression Risk in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study in Korea | 2.4 | 8 | Citations (PDF) |
| 66 | Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression | 8.8 | 111 | Citations (PDF) |
| 67 | Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea | 0.9 | 16 | Citations (PDF) |
| 68 | Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression | 4.5 | 29 | Citations (PDF) |
| 69 | Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder | 4.5 | 14 | Citations (PDF) |
| 70 | Elevated Amygdala Activity in Young Adults With Familial Risk for Depression: A Potential Marker of Low Resilience | 1.2 | 14 | Citations (PDF) |
| 71 | Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19–34: A nationwide population study in South Korea | 4.5 | 23 | Citations (PDF) |
| 72 | Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder | 12.4 | 83 | Citations (PDF) |
| 73 | The Impact of Childhood Trauma, Hallucinations, and Emotional Reactivity on Delusional Ideation | 1.4 | 6 | Citations (PDF) |
| 74 | Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study | 1.2 | 13 | Citations (PDF) |
| 75 | PET imaging of neurotransmission using direct parametric reconstruction | 4.4 | 5 | Citations (PDF) |
| 76 | Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study | 8.8 | 27 | Citations (PDF) |
| 77 | Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review | 4.5 | 33 | Citations (PDF) |
| 78 | John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials | 4.3 | 27 | Citations (PDF) |
| 79 | Dose-Dependent Effects of EPA Supplementation on Plasma Specialized Pro-Resolving Mediators in Major Depressive Disorder Patients with Chronic Inflammation | 0.2 | 0 | Citations (PDF) |
| 80 | Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study | 4.5 | 5 | Citations (PDF) |
| 81 | Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia | 2.4 | 5 | Citations (PDF) |
| 82 | Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study | 2.9 | 29 | Citations (PDF) |
| 83 | Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse | 5.4 | 35 | Citations (PDF) |
| 84 | Success and efficiency of phase 2/3 adjunctive trials for MDD funded by industry: a systematic review | 7.8 | 16 | Citations (PDF) |
| 85 | An electroencephalographic signature predicts antidepressant response in major depression | 29.8 | 263 | Citations (PDF) |
| 86 | All Suicidal Ideation Is Not Created Equal: Two Cases of Suicide Attempts During Maintenance Ketamine Treatment | 8.8 | 10 | Citations (PDF) |
| 87 | Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis | 4.0 | 11 | Citations (PDF) |
| 88 | Evaluating the combination of a Brief Motivational Intervention plus Cognitive Behavioral Therapy for Depression and heavy episodic drinking in college students. | 1.7 | 17 | Citations (PDF) |
| 89 | Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial of a Kappa-Selective Opioid Receptor Antagonist Augmentation in Treatment-Resistant Depression 2020, 33, 18-26 | | 9 | Citations (PDF) |
| 90 | Increased Morbidity of Major Depressive Disorder After Thyroidectomy: A Nationwide Population-Based Study in South Korea | 4.4 | 28 | Citations (PDF) |
| 91 | Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder | 5.3 | 21 | Citations (PDF) |
| 92 | Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) | 2.7 | 528 | Citations (PDF) |
| 93 | Community-Delivered Heated Hatha Yoga as a Treatment for Depressive Symptoms: An Uncontrolled Pilot Study | 1.9 | 17 | Citations (PDF) |
| 94 | Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression | 2.9 | 60 | Citations (PDF) |
| 95 | Pre-treatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: A 12-week follow-up study | 4.0 | 16 | Citations (PDF) |
| 96 | Model‐Informed Approach to Assess the Treatment Effect Conditional to the Level of Placebo Response | 4.7 | 5 | Citations (PDF) |
| 97 | Ratio of plasma BDNF to leptin levels are associated with treatment response in major depressive disorder but not in panic disorder: A 12-week follow-up study | 4.5 | 10 | Citations (PDF) |
| 98 | Longer-term open-label study of adjunctive riluzole in treatment-resistant depression | 4.5 | 18 | Citations (PDF) |
| 99 | Brain regulation of emotional conflict predicts antidepressant treatment response for depression | 9.1 | 48 | Citations (PDF) |
| 100 | Multiple types of somatic pain increase suicide attempts and depression: A nationwide community sample of Korean adults | 4.0 | 16 | Citations (PDF) |
| 101 | Comparison of suicide attempts in individuals with major depressive disorder with and without history of subthreshold hypomania: A nationwide community sample of Korean adults✰,✰✰ | 4.5 | 7 | Citations (PDF) |
| 102 | Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial | 8.2 | 29 | Citations (PDF) |
| 103 | Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response | 4.5 | 16 | Citations (PDF) |
| 104 | Deformities of the Globus Pallidus are Associated with Severity of Suicidal Ideation and Impulsivity in Patients with Major Depressive Disorder | 3.4 | 26 | Citations (PDF) |
| 105 | Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study | 4.8 | 29 | Citations (PDF) |
| 106 | Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia | 12.4 | 25 | Citations (PDF) |
| 107 | Childhood trauma history is linked to abnormal brain connectivity in major depression | 7.5 | 208 | Citations (PDF) |
| 108 | 3.4 CHANGES IN AMYGDALA AND HIPPOCAMPAL FUNCTIONAL CONNECTIVITY IN SUBCLINICAL PSYCHOSIS: RELATIONSHIP TO SYMPTOM PERSISTENCE, PARANOIA AND ABERRANT SALIENCE | 3.9 | 0 | Citations (PDF) |
| 109 | Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia | 1.7 | 23 | Citations (PDF) |
| 110 | Paranoid Ideation Without Psychosis Is Associated With Depression, Anxiety, and Suicide Attempts in General Population | 1.0 | 12 | Citations (PDF) |
| 111 | Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression | 1.9 | 31 | Citations (PDF) |
| 112 | Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression | 4.0 | 43 | Citations (PDF) |
| 113 | Heart rate variability for treatment response between patients with major depressive disorder versus panic disorder: A 12-week follow-up study | 4.5 | 36 | Citations (PDF) |
| 114 | Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial | 5.4 | 69 | Citations (PDF) |
| 115 | Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control | 4.5 | 32 | Citations (PDF) |
| 116 | Understanding the effects of emotional reactivity on depression and suicidal thoughts and behaviors: Moderating effects of childhood adversity and resilience | 4.5 | 102 | Citations (PDF) |
| 117 | Tachyphylaxis in major depressive disorder: A review of the current state of research | 4.5 | 39 | Citations (PDF) |
| 118 | Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial | 4.5 | 158 | Citations (PDF) |
| 119 | Effect of Korean Red Ginseng in individuals exposed to high stress levels: a 6-week, double-blind, randomized, placebo-controlled trial | 5.0 | 31 | Citations (PDF) |
| 120 | Discovery and replication of cerebral blood flow differences in major depressive disorder | 7.8 | 57 | Citations (PDF) |
| 121 | Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals | 7.8 | 45 | Citations (PDF) |
| 122 | Risks of Completed Suicide of Community Individuals with ICD-10 Disorders Across Age Groups: A Nationwide Population-Based Nested Case-Control Study in South Korea | 1.6 | 25 | Citations (PDF) |
| 123 | Design and Methods of the Korean National Investigations of 70,000 Suicide Victims Through Police Records (The KNIGHTS Study) | 1.6 | 10 | Citations (PDF) |
| 124 | Prospective association between major depressive disorder and leukocyte telomere length over two years | 2.7 | 38 | Citations (PDF) |
| 125 | Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression | 12.4 | 180 | Citations (PDF) |
| 126 | Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence | 1.7 | 22 | Citations (PDF) |
| 127 | Is It Time for Going Beyond the <i>P</i>‐Value Paradigm With the Estimation of the Probability of Clinical Benefit as a Criterion for Assessing the Outcomes of a Clinical Trial? A Case Study in Patients With Major Depressive Disorder | 1.9 | 0 | Citations (PDF) |
| 128 | S-Adenosyl Methionine and Transmethylation Pathways in Neuropsychiatric Diseases Throughout Life | 6.1 | 109 | Citations (PDF) |
| 129 | Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study | 2.9 | 17 | Citations (PDF) |
| 130 | A randomized controlled dosing study of Iyengar yoga and coherent breathing for the treatment of major depressive disorder: Impact on suicidal ideation and safety findings | 3.0 | 27 | Citations (PDF) |
| 131 | The Effects of Tai Chi on Sleep Quality in Chinese American Patients With Major Depressive Disorder: A Pilot Study | 1.9 | 18 | Citations (PDF) |
| 132 | Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement | 4.2 | 51 | Citations (PDF) |
| 133 | Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD) | 1.5 | 25 | Citations (PDF) |
| 134 | Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study | 1.8 | 33 | Citations (PDF) |
| 135 | Alcohol-induced disinhibition is associated with impulsivity, depression, and suicide attempt: A nationwide community sample of Korean adults | 4.5 | 23 | Citations (PDF) |
| 136 | Outcomes of an online computerized cognitive behavioral treatment program for treating chinese patients with depression: A pilot study | 2.5 | 24 | Citations (PDF) |
| 137 | Harmonization of cortical thickness measurements across scanners and sites | 4.4 | 1,396 | Citations (PDF) |
| 138 | Efficacy of adjunctive low-dose cariprazine in major depressive disorder | 1.2 | 54 | Citations (PDF) |
| 139 | Mechanisms of Perceived Treatment Assignment and Subsequent Expectancy Effects in a Double Blind Placebo Controlled RCT of Major Depression | 2.4 | 19 | Citations (PDF) |
| 140 | Increased adrenocorticotropic hormone (ACTH) levels predict severity of depression after six months of follow-up in outpatients with major depressive disorder | 3.1 | 46 | Citations (PDF) |
| 141 | Anxiety attacks with or without life-threatening situations, major depressive disorder, and suicide attempt: a nationwide community sample of Korean adults | 3.1 | 5 | Citations (PDF) |
| 142 | Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial | 2.1 | 136 | Citations (PDF) |
| 143 | Binge eating, trauma, and suicide attempt in community adults with major depressive disorder | 2.3 | 18 | Citations (PDF) |
| 144 | Statistical harmonization corrects site effects in functional connectivity measurements from multi‐site fMRI data | 3.5 | 441 | Citations (PDF) |
| 145 | Sex Differences in the Association between Heavy Drinking and Behavioral Distress Tolerance and Emotional Reactivity Among Non-Depressed College Students | 1.7 | 15 | Citations (PDF) |
| 146 | Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder | 5.3 | 71 | Citations (PDF) |
| 147 | Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses | 1.1 | 8 | Citations (PDF) |
| 148 | Placebo Response as a Latent Characteristic: Application to Analysis of Sequential Parallel Comparison Design Studies | 3.4 | 6 | Citations (PDF) |
| 149 | Development and evaluation of a multimodal marker of major depressive disorder | 3.5 | 46 | Citations (PDF) |
| 150 | CBT Delivered in a Specialized Depression Clinic for College Students with Depressive Symptoms | 1.2 | 6 | Citations (PDF) |
| 151 | Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) | 7.8 | 363 | Citations (PDF) |
| 152 | Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies | 7.8 | 64 | Citations (PDF) |
| 153 | Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation | 2.4 | 101 | Citations (PDF) |
| 154 | Inflammatory cytokines in major depressive disorder: A case–control study | 2.4 | 69 | Citations (PDF) |
| 155 | Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings From the EMBARC Study | 1.2 | 21 | Citations (PDF) |
| 156 | Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study | 3.3 | 35 | Citations (PDF) |
| 157 | A comparison of structural connectivity in anxious depression versus non-anxious depression | 2.9 | 36 | Citations (PDF) |
| 158 | Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) study | 1.2 | 23 | Citations (PDF) |
| 159 | Cortical thickness is not associated with current depression in a clinical treatment study | 3.5 | 18 | Citations (PDF) |
| 160 | A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder | 5.3 | 45 | Citations (PDF) |
| 161 | Internet Game Addiction, Depression, and Escape From Negative Emotions in Adulthood | 1.0 | 90 | Citations (PDF) |
| 162 | Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison | 2.9 | 157 | Citations (PDF) |
| 163 | Guarding the Gate | 1.7 | 27 | Citations (PDF) |
| 164 | Development and validation study of the Smartphone Overuse Screening Questionnaire | 3.1 | 45 | Citations (PDF) |
| 165 | Reduced orbitofrontal-thalamic functional connectivity related to suicidal ideation in patients with major depressive disorder | 3.4 | 97 | Citations (PDF) |
| 166 | Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants | 4.5 | 47 | Citations (PDF) |
| 167 | [P4–543]: COGNITIVE FUNCTION AS A PROXY OF FINANCIAL DECISION MAKING IN OLDER PRIMARY CARE ADULTS | 0.5 | 0 | Citations (PDF) |
| 168 | Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies | 4.2 | 13 | Citations (PDF) |
| 169 | Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea | 2.3 | 56 | Citations (PDF) |
| 170 | Comparisons of Subthreshold Versus Full Posttraumatic Stress Disorder Distinguished by Subjective Functional Impairment Among Train Drivers: A Population-Based Nationwide Study in South Korea | 1.6 | 8 | Citations (PDF) |
| 171 | Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study | 1.6 | 3 | Citations (PDF) |
| 172 | Gender Differences in Somatic Symptoms and Current Suicidal Risk in Outpatients with Major Depressive Disorder | 1.6 | 27 | Citations (PDF) |
| 173 | Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia | 1.7 | 50 | Citations (PDF) |
| 174 | Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder | 1.2 | 7 | Citations (PDF) |
| 175 | Loss of sexual interest and premenstrual mood change in women with postpartum versus non-postpartum depression: A nationwide community sample of Korean adults | 4.5 | 6 | Citations (PDF) |
| 176 | A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder | 3.0 | 3 | Citations (PDF) |
| 177 | Examining the efficacy of d-cycloserine to augment therapeutic learning in depression | 1.6 | 12 | Citations (PDF) |
| 178 | Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice | 1.9 | 23 | Citations (PDF) |
| 179 | A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression | 8.8 | 470 | Citations (PDF) |
| 180 | Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design | 2.9 | 277 | Citations (PDF) |
| 181 | Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses | 8.8 | 365 | Citations (PDF) |
| 182 | Cross-national differences in hypochondriasis symptoms between Korean and American outpatients with major depressive disorder | 3.1 | 5 | Citations (PDF) |
| 183 | Major depressive disorder | 47.2 | 1,828 | Citations (PDF) |
| 184 | Linking major depression and the neural substrates of associative processing | 1.9 | 29 | Citations (PDF) |
| 185 | Ziprasidone augmentation for anxious depression | 1.2 | 9 | Citations (PDF) |
| 186 | PS89. Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study | 2.7 | 1 | Citations (PDF) |
| 187 | Lifetime suicidal ideation and attempt in adults with full major depressive disorder versus sustained depressed mood | 4.5 | 11 | Citations (PDF) |
| 188 | Response Surface Analysis and Nonlinear Optimization Algorithm for Maximization of Clinical Drug Performance: Application to Extended‐Release and Long‐Acting Injectable Paliperidone | 1.9 | 15 | Citations (PDF) |
| 189 | A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER | 4.0 | 49 | Citations (PDF) |
| 190 | Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial | 8.8 | 169 | Citations (PDF) |
| 191 | Obsessive-Compulsive Symptoms as a Risk Factor for Suicidality in U.S. College Students | 2.7 | 29 | Citations (PDF) |
| 192 | Relationship between placebo response rate and clinical trial outcome in bipolar depression | 2.9 | 23 | Citations (PDF) |
| 193 | Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression | 5.3 | 57 | Citations (PDF) |
| 194 | Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder | 1.6 | 27 | Citations (PDF) |
| 195 | Major depressive disorder with psychosis-like symptoms in Latinos: treatment with and without antipsychotic augmentation | 0.7 | 1 | Citations (PDF) |
| 196 | THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS | 4.0 | 39 | Citations (PDF) |
| 197 | The Role of Anger/Hostility in Treatment-Resistant Depression | 1.0 | 21 | Citations (PDF) |
| 198 | Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process | 3.5 | 156 | Citations (PDF) |
| 199 | Placebo non‐response measure in sequential parallel comparison design studies | 1.7 | 17 | Citations (PDF) |
| 200 | Celebrity Suicides and Their Differential Influence on Suicides in the General Population: A National Population-Based Study in Korea | 1.6 | 16 | Citations (PDF) |
| 201 | Changes in cognitive symptoms after a buspirone–melatonin combination treatment for Major Depressive Disorder | 2.9 | 26 | Citations (PDF) |
| 202 | A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response | 5.3 | 9 | Citations (PDF) |
| 203 | Genetic Differences in the Immediate Transcriptome Response to Stress Predict Risk-Related Brain Function and Psychiatric Disorders | 11.0 | 119 | Citations (PDF) |
| 204 | Illness Progression, Recent Stress, and Morphometry of Hippocampal Subfields and Medial Prefrontal Cortex in Major Depression | 5.4 | 293 | Citations (PDF) |
| 205 | Illness beliefs of Chinese American immigrants with major depressive disorder in a primary care setting | 2.5 | 42 | Citations (PDF) |
| 206 | Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study | 8.8 | 94 | Citations (PDF) |
| 207 | Anhedonia in melancholic and non-melancholic depressive disorders | 4.5 | 68 | Citations (PDF) |
| 208 | Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study | 4.5 | 13 | Citations (PDF) |
| 209 | Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study | 8.8 | 53 | Citations (PDF) |
| 210 | Efficacy of ziprasidone monotherapy in patients with anxious depression: A 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial | 2.9 | 6 | Citations (PDF) |
| 211 | Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls | 2.7 | 52 | Citations (PDF) |
| 212 | Association between physician beliefs regarding assigned treatment and clinical response: Re-analysis of data from the Hypericum Depression Trial Study Group | 2.5 | 18 | Citations (PDF) |
| 213 | Screening for Suicide Risk in the College Population | 1.2 | 19 | Citations (PDF) |
| 214 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Augmentation of a Nicotinic Acetylcholine Receptor Partial Agonist in Depression | 1.7 | 16 | Citations (PDF) |
| 215 | Predictors of placebo response in bipolar depression | 1.2 | 20 | Citations (PDF) |
| 216 | Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder | 5.3 | 28 | Citations (PDF) |
| 217 | The pro-inflammatory profile of depressed patients is (partly) related to obesity | 2.9 | 53 | Citations (PDF) |
| 218 | Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder | 4.5 | 29 | Citations (PDF) |
| 219 | Efficacy and safety of a form of cranial electrical stimulation (CES) as an add-on intervention for treatment-resistant major depressive disorder: A three week double blind pilot study | 2.9 | 20 | Citations (PDF) |
| 220 | Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study | 5.3 | 99 | Citations (PDF) |
| 221 | Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study | 2.3 | 22 | Citations (PDF) |
| 222 | Paraquat Prohibition and Change in the Suicide Rate and Methods in South Korea | 2.3 | 60 | Citations (PDF) |
| 223 | A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders | 0.6 | 25 | Citations (PDF) |
| 224 | Review of Suicide Prevention Programs: Massachusetts, United States, in Comparison with Seoul | 1.6 | 10 | Citations (PDF) |
| 225 | A Double-Blind, Randomized, Placebo-Controlled Clinical Trial ofS-Adenosyl-l-Methionine (SAMe) Versus Escitalopram in Major Depressive Disorder | 1.8 | 138 | Citations (PDF) |
| 226 | Effectiveness of the Relaxation Response-Based Group Intervention for Treating Depressed Chinese American Immigrants: A Pilot Study | 2.9 | 12 | Citations (PDF) |
| 227 | CLINICAL RELEVANCE OF FATIGUE AS A RESIDUAL SYMPTOM IN MAJOR DEPRESSIVE DISORDER | 4.0 | 145 | Citations (PDF) |
| 228 | Childhood Trauma, Parental Death, and Their Co-occurrence in Relation to Current Suicidality Risk in Adults | 1.0 | 14 | Citations (PDF) |
| 229 | Improvement in Subjective and Objective Neurocognitive Functions in Patients With Major Depressive Disorder | 1.7 | 18 | Citations (PDF) |
| 230 | Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder | 1.2 | 6 | Citations (PDF) |
| 231 | An Electronic Health Records Study of Long-Term Weight Gain Following Antidepressant Use | 12.4 | 138 | Citations (PDF) |
| 232 | Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder | 4.5 | 26 | Citations (PDF) |
| 233 | S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response | 4.5 | 63 | Citations (PDF) |
| 234 | Associations Among Smoking, Anhedonia, and Reward Learning in Depression | 2.9 | 74 | Citations (PDF) |
| 235 | Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC) | 4.5 | 38 | Citations (PDF) |
| 236 | Fatigue across the CNS spectrum: a clinical review | 1.5 | 2 | Citations (PDF) |
| 237 | Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients | 1.0 | 10 | Citations (PDF) |
| 238 | Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders | 4.5 | 59 | Citations (PDF) |
| 239 | Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder | 3.8 | 81 | Citations (PDF) |
| 240 | The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder | 4.0 | 58 | Citations (PDF) |
| 241 | Rare Copy Number Variation in Treatment-Resistant Major Depressive Disorder | 5.4 | 69 | Citations (PDF) |
| 242 | Feelings of worthlessness, traumatic experience, and their comorbidity in relation to lifetime suicide attempt in community adults with major depressive disorder | 4.5 | 41 | Citations (PDF) |
| 243 | Sleep Quality, Posttraumatic Stress, Depression, and Human Errors in Train Drivers: A Population-Based Nationwide Study in South KoreaSleep, 2014, 37, 1969-1975 | 0.9 | 16 | Citations (PDF) |
| 244 | Evaluation of Opioid Modulation in Major Depressive Disorder | 5.3 | 160 | Citations (PDF) |
| 245 | Using online social media, Facebook, in screening for major depressive disorder among college students | 4.1 | 43 | Citations (PDF) |
| 246 | Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder | 3.1 | 27 | Citations (PDF) |
| 247 | RELATIONSHIP BETWEEN SLEEP DISTURBANCE AND DEPRESSION, ANXIETY, AND FUNCTIONING IN COLLEGE STUDENTS | 4.0 | 206 | Citations (PDF) |
| 248 | A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies | 1.7 | 48 | Citations (PDF) |
| 249 | Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos | 4.5 | 16 | Citations (PDF) |
| 250 | Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder | 4.5 | 27 | Citations (PDF) |
| 251 | Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study | 2.1 | 66 | Citations (PDF) |
| 252 | Combined MI + CBT for Depressive Symptoms and Binge Drinking Among Young Adults: Two Case Studies | 0.9 | 4 | Citations (PDF) |
| 253 | Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies | 4.8 | 66 | Citations (PDF) |
| 254 | Relationship Between Obesity and Depression | 2.2 | 53 | Citations (PDF) |
| 255 | Massachusetts General Hospital SAFER Criteria for Clinical Trials and Research | 1.9 | 28 | Citations (PDF) |
| 256 | Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies | 8.8 | 241 | Citations (PDF) |
| 257 | Correlates of Irritability in College Students With Depressive Symptoms | 1.0 | 22 | Citations (PDF) |
| 258 | The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression | 1.2 | 8 | Citations (PDF) |
| 259 | Childhood Parental Death and Lifetime Suicide Attempt of the Opposite‐Gender Offspring in a Nationwide Community Sample of Korea | 2.3 | 20 | Citations (PDF) |
| 260 | Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John’s Wort in Major Depressive Disorder | 1.7 | 5 | Citations (PDF) |
| 261 | A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Augmentation in Treatment-Resistant Major Depressive Disorder | 1.8 | 83 | Citations (PDF) |
| 262 | S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders | 6.3 | 17 | Citations (PDF) |
| 263 | Severe Depression | 6.3 | 42 | Citations (PDF) |
| 264 | GABAB Receptors, Schizophrenia and Sleep Dysfunction | 6.3 | 230 | Citations (PDF) |
| 265 | A Randomized, Controlled, Pilot Study of Acamprosate Added to Escitalopram in Adults With Major Depressive Disorder and Alcohol Use Disorder | 1.7 | 21 | Citations (PDF) |
| 266 | Major Depressive Disorder With Psychosis-Like Symptoms Among Latinos | 2.0 | 13 | Citations (PDF) |
| 267 | The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale | 2.4 | 24 | Citations (PDF) |
| 268 | The Inflammatory Hypothesis of Depression | 1.1 | 4 | Citations (PDF) |
| 269 | Antidepressant Response in Patients With Major Depression Exposed to NSAIDs: A Pharmacovigilance Study | 8.8 | 74 | Citations (PDF) |
| 270 | l
-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials | 8.8 | 256 | Citations (PDF) |
| 271 | Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants | 1.9 | 49 | Citations (PDF) |
| 272 | The Quick Inventory of Depressive Symptomatology, Clinician Rated and Self-report | 1.0 | 28 | Citations (PDF) |
| 273 | Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report | 2.7 | 27 | Citations (PDF) |
| 274 | Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial | 1.0 | 72 | Citations (PDF) |
| 275 | An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery | 2.9 | 60 | Citations (PDF) |
| 276 | Cross-Cultural Aspects of Depression Management in Primary Care | 5.3 | 10 | Citations (PDF) |
| 277 | Cognitive therapy for anxious depression in STAR⁎D: What have we learned? | 4.5 | 48 | Citations (PDF) |
| 278 | What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? | 4.0 | 33 | Citations (PDF) |
| 279 | EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL | 4.0 | 19 | Citations (PDF) |
| 280 | CLINICAL OUTCOMES IN MEASUREMENT-BASED TREATMENT (COMET): A TRIAL OF DEPRESSION MONITORING AND FEEDBACK TO PRIMARY CARE PHYSICIANS | 4.0 | 63 | Citations (PDF) |
| 281 | Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial | 2.6 | 30 | Citations (PDF) |
| 282 | Antidepressant Effects on Emotional Temperament: Toward a Biobehavioral Research Paradigm for Major Depressive Disorder | 5.0 | 41 | Citations (PDF) |
| 283 | Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial | 2.9 | 83 | Citations (PDF) |
| 284 | Development of a clinical global impression scale for fatigue | 2.9 | 32 | Citations (PDF) |
| 285 | A mega-analysis of genome-wide association studies for major depressive disorder | 7.8 | 1,048 | Citations (PDF) |
| 286 | Do Suicidal Thoughts or Behaviors Recur During a Second Antidepressant Treatment Trial? | 1.8 | 9 | Citations (PDF) |
| 287 | Eszopiclone Treatment for Insomnia | 0.6 | 14 | Citations (PDF) |
| 288 | Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder | 12.6 | 124 | Citations (PDF) |
| 289 | Using the Electronic Medical Record to Examine Racial and Ethnic Differences in Depression Diagnosis and Treatment in a Primary Care Population | 0.1 | 0 | Citations (PDF) |
| 290 | The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study | 1.7 | 16 | Citations (PDF) |
| 291 | A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females | 1.7 | 11 | Citations (PDF) |
| 292 | Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St Johnʼs wort (Hypericum perforatum) versus a SSRI | 1.2 | 9 | Citations (PDF) |
| 293 | The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression | 2.9 | 45 | Citations (PDF) |
| 294 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report | 4.5 | 46 | Citations (PDF) |
| 295 | Assessing anxious features in depressed outpatients | 2.2 | 18 | Citations (PDF) |
| 296 | The Engagement Interview Protocol (EIP): improving the acceptance of mental health treatment among Chinese immigrants | 0.7 | 17 | Citations (PDF) |
| 297 | Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study | 8.8 | 368 | Citations (PDF) |
| 298 | Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial | 2.0 | 33 | Citations (PDF) |
| 299 | A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression | 1.8 | 36 | Citations (PDF) |
| 300 | Improved Insomnia Symptoms and Sleep-Related Next-Day Functioning in Patients With Comorbid Major Depressive Disorder and Insomnia Following Concomitant Zolpidem Extended-Release 12.5 mg and Escitalopram Treatment | 1.8 | 82 | Citations (PDF) |
| 301 | Association Between Patient Beliefs Regarding Assigned Treatment and Clinical Response | 1.8 | 52 | Citations (PDF) |
| 302 | Concise Health Risk Tracking Scale | 1.8 | 149 | Citations (PDF) |
| 303 | Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder | 1.5 | 50 | Citations (PDF) |
| 304 | Culturally Sensitive Collaborative Treatment for Depressed Chinese Americans in Primary Care | 2.7 | 112 | Citations (PDF) |
| 305 | Do atypical features affect outcome in depressed outpatients treated with citalopram? | 2.7 | 60 | Citations (PDF) |
| 306 | S
-Adenosyl Methionine (SAMe) Augmentation of Serotonin Reuptake Inhibitors for Antidepressant Nonresponders With Major Depressive Disorder: A Double-Blind, Randomized Clinical Trial | 8.8 | 293 | Citations (PDF) |
| 307 | Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study | 1.2 | 20 | Citations (PDF) |
| 308 | Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment | 1.7 | 23 | Citations (PDF) |
| 309 | The impact of diabetes on depression treatment outcomes | 2.6 | 28 | Citations (PDF) |
| 310 | Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine | 2.3 | 13 | Citations (PDF) |
| 311 | Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study | 5.3 | 125 | Citations (PDF) |
| 312 | Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response | 12.6 | 107 | Citations (PDF) |
| 313 | Genome-Wide Association Study of Suicide Attempts in Mood Disorder Patients | 8.8 | 148 | Citations (PDF) |
| 314 | Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence | 5.4 | 391 | Citations (PDF) |
| 315 | Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes | 2.9 | 78 | Citations (PDF) |
| 316 | RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ) | 5.0 | 150 | Citations (PDF) |
| 317 | Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: A meta-analysis | 1.0 | 15 | Citations (PDF) |
| 318 | Microstructural Abnormalities in Subcortical Reward Circuitry of Subjects with Major Depressive Disorder | 2.3 | 120 | Citations (PDF) |
| 319 | Complementary and Alternative Medicine in Major Depressive Disorder | 1.8 | 123 | Citations (PDF) |
| 320 | Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder | 0.7 | 25 | Citations (PDF) |
| 321 | Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder | 2.4 | 9 | Citations (PDF) |
| 322 | Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report | 1.2 | 2 | Citations (PDF) |
| 323 | Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report | 8.8 | 219 | Citations (PDF) |
| 324 | Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients | 5.3 | 94 | Citations (PDF) |
| 325 | Reduced Caudate and Nucleus Accumbens Response to Rewards in Unmedicated Individuals With Major Depressive Disorder | 8.8 | 1,125 | Citations (PDF) |
| 326 | Sex differences in response to citalopram: A STAR∗D report | 2.9 | 179 | Citations (PDF) |
| 327 | Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder | 4.5 | 23 | Citations (PDF) |
| 328 | Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STAR⁎D study | 4.5 | 95 | Citations (PDF) |
| 329 | Diurnal mood variation in outpatients with major depressive disorder | 4.0 | 28 | Citations (PDF) |
| 330 | Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR * D trial | 4.0 | 29 | Citations (PDF) |
| 331 | Release bias in accessing medical records in clinical trials: a STAR*D report | 2.2 | 1 | Citations (PDF) |
| 332 | Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome | 2.9 | 135 | Citations (PDF) |
| 333 | Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder | 3.1 | 112 | Citations (PDF) |
| 334 | Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study | 3.1 | 169 | Citations (PDF) |
| 335 | Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD | 1.0 | 357 | Citations (PDF) |
| 336 | Frontal EEG predictors of treatment outcome in major depressive disorder | 1.0 | 169 | Citations (PDF) |
| 337 | The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report | 5.0 | 11 | Citations (PDF) |
| 338 | Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies | 1.2 | 39 | Citations (PDF) |
| 339 | Zolpidem Extended-Release Improves Sleep and Next-Day Symptoms in Comorbid Insomnia and Generalized Anxiety Disorder | 1.7 | 72 | Citations (PDF) |
| 340 | Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine | 2.7 | 37 | Citations (PDF) |
| 341 | Do Depressed Patients With Diabetes Experience More Side Effects When Treated With Citalopram Than Their Counterparts Without Diabetes? | 0.7 | 2 | Citations (PDF) |
| 342 | Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D | 2.4 | 96 | Citations (PDF) |
| 343 | Redefining Affective Disorders: Relevance for Drug Development | 5.0 | 16 | Citations (PDF) |
| 344 | A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: A STAR⁎D report | 4.5 | 16 | Citations (PDF) |
| 345 | Reduced hedonic capacity in major depressive disorder: Evidence from a probabilistic reward task | 2.9 | 714 | Citations (PDF) |
| 346 | Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches | 5.4 | 255 | Citations (PDF) |
| 347 | Brain Bioenergetics and Response to Triiodothyronine Augmentation in Major Depressive Disorder | 5.4 | 165 | Citations (PDF) |
| 348 | Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression | 3.1 | 31 | Citations (PDF) |
| 349 | Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder | 3.1 | 45 | Citations (PDF) |
| 350 | A Double‐Blind, Randomized, Pilot Dose‐Finding Study of Maca Root (L. Meyenii) for the Management of SSRI‐Induced Sexual Dysfunction | 5.0 | 80 | Citations (PDF) |
| 351 | Treatment Outcomes for Older Depressed Patients With Earlier Versus Late Onset of First Depressive Episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report | 1.7 | 41 | Citations (PDF) |
| 352 | Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms | 3.7 | 65 | Citations (PDF) |
| 353 | Adaptation of Dialectical Behavior Therapy Skills Training Group for Treatment-Resistant Depression | 1.0 | 155 | Citations (PDF) |
| 354 | Selecting Among Second-Step Antidepressant Medication Monotherapies | 12.6 | 164 | Citations (PDF) |
| 355 | Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report | 8.8 | 872 | Citations (PDF) |
| 356 | Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study | 5.3 | 97 | Citations (PDF) |
| 357 | Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression | 1.4 | 56 | Citations (PDF) |
| 358 | Association of a Polymorphism Near CREB1 With Differential Aversion Processing in the Insula of Healthy Participants | 12.6 | 49 | Citations (PDF) |
| 359 | The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder | 1.7 | 499 | Citations (PDF) |
| 360 | Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report | 1.1 | 22 | Citations (PDF) |
| 361 | Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study | 8.8 | 178 | Citations (PDF) |
| 362 | Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report | 1.1 | 2 | Citations (PDF) |
| 363 | A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders | 1.7 | 60 | Citations (PDF) |
| 364 | A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder | 1.3 | 62 | Citations (PDF) |
| 365 | An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder | 0.6 | 46 | Citations (PDF) |
| 366 | A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder | 1.2 | 31 | Citations (PDF) |
| 367 | Clinically Relevant Findings from STAR*D | 0.3 | 13 | Citations (PDF) |
| 368 | The STAR*D study: treating depression in the real world. | 1.3 | 211 | Citations (PDF) |
| 369 | The History and Current State of Antidepressant Clinical Trial Design | 1.8 | 71 | Citations (PDF) |
| 370 | Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder | 0.7 | 43 | Citations (PDF) |
| 371 | Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report | 8.8 | 312 | Citations (PDF) |
| 372 | Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study | 12.6 | 135 | Citations (PDF) |
| 373 | Modafinil Augmentation of Selective Serotonin Reuptake Inhibitor Therapy in MDD Partial Responders with Persistent Fatigue and Sleepiness | 1.4 | 102 | Citations (PDF) |
| 374 | The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study | 1.4 | 25 | Citations (PDF) |
| 375 | Insured and Non-insured Depressed Outpatients: How Do They Compare? | 1.4 | 5 | Citations (PDF) |
| 376 | Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report | 8.8 | 69 | Citations (PDF) |
| 377 | Effect of Age at Onset on the Course of Major Depressive Disorder | 8.8 | 480 | Citations (PDF) |
| 378 | Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression | 12.6 | 214 | Citations (PDF) |
| 379 | Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis | 1.8 | 94 | Citations (PDF) |
| 380 | Extreme response style in recurrent and chronically depressed patients: Change with antidepressant administration and stability during continuation treatment. | 2.3 | 28 | Citations (PDF) |
| 381 | Comparison of Quality of Life Measures in a Depressed Population | 1.0 | 28 | Citations (PDF) |
| 382 | Major Depressive Disorder with Anger Attacks and Cardiovascular Risk Factors | 1.3 | 16 | Citations (PDF) |
| 383 | Perceived Stress and Cognitive Vulnerability Mediate the Effects of Personality Disorder Comorbidity on Treatment Outcome in Major Depressive Disorder | 1.0 | 19 | Citations (PDF) |
| 384 | Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder | 3.1 | 28 | Citations (PDF) |
| 385 | Pain in depression: STAR*D study findings | 2.1 | 73 | Citations (PDF) |
| 386 | A meta-analysis of clinical trials comparing milnacipran, a serotonin–norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder | 1.0 | 48 | Citations (PDF) |
| 387 | Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study | 2.6 | 31 | Citations (PDF) |
| 388 | A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression | 2.1 | 39 | Citations (PDF) |
| 389 | Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents | 5.4 | 285 | Citations (PDF) |
| 390 | Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression | 2.7 | 80 | Citations (PDF) |
| 391 | Family history of mood disorder and characteristics of major depressive disorder: A STAR∗D (sequenced treatment alternatives to relieve depression) study | 2.9 | 73 | Citations (PDF) |
| 392 | The STAR*D project results: A comprehensive review of findings | 5.3 | 661 | Citations (PDF) |
| 393 | Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment | 2.6 | 91 | Citations (PDF) |
| 394 | The Role of Cognitive-Behavioral Therapy and Fluoxetine in Prevention of Recurrence of Major Depressive Disorder | 1.5 | 14 | Citations (PDF) |
| 395 | Clinical Features of Depression in Outpatients With and Without Co-Occurring General Medical Conditions in STAR*D | 0.7 | 60 | Citations (PDF) |
| 396 | Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression | 34.6 | 995 | Citations (PDF) |
| 397 | Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment | 6.5 | 453 | Citations (PDF) |
| 398 | Somatic Symptoms in Outpatients With Major Depressive Disorder Treated With Fluoxetine | 2.6 | 22 | Citations (PDF) |
| 399 | An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report | 5.4 | 367 | Citations (PDF) |
| 400 | Anger Attacks in Major Depressive Disorder and Serum Levels of Homocysteine | 5.4 | 30 | Citations (PDF) |
| 401 | Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder | 5.4 | 457 | Citations (PDF) |
| 402 | Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging | 5.4 | 470 | Citations (PDF) |
| 403 | Resolution of Sleepiness and Fatigue in Major Depressive Disorder: A Comparison of Bupropion and the Selective Serotonin Reuptake Inhibitors | 5.4 | 331 | Citations (PDF) |
| 404 | A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder | 2.7 | 45 | Citations (PDF) |
| 405 | Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report | 8.8 | 319 | Citations (PDF) |
| 406 | What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension | 2.7 | 167 | Citations (PDF) |
| 407 | A Survey of Antidepressant Prescribing Practices in Major Depression with Comorbid Attention-Deficit Hyperactivity Disorder | 1.7 | 0 | Citations (PDF) |
| 408 | Clinical characteristics of depressed patients with comorbid diabetes mellitus | 1.2 | 6 | Citations (PDF) |
| 409 | Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort | 1.9 | 95 | Citations (PDF) |
| 410 | Adjunctive atomoxetine for residual fatigue in major depressive disorder | 2.9 | 25 | Citations (PDF) |
| 411 | Management of depression relapse: Re-initiation of duloxetine treatment or dose increase | 2.9 | 32 | Citations (PDF) |
| 412 | Differences in cognitive factors between “true drug” versus “placebo pattern” response to fluoxetine as defined by pattern analysis | 1.7 | 3 | Citations (PDF) |
| 413 | Remissions in Maternal Depression and Child Psychopathology | 16.6 | 567 | Citations (PDF) |
| 414 | A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report | 8.8 | 301 | Citations (PDF) |
| 415 | Clinical and Demographic Factors Associated With DSM-IV Melancholic Depression | 1.4 | 113 | Citations (PDF) |
| 416 | Pharmacological approaches to the treatment of residual symptoms | 4.8 | 40 | Citations (PDF) |
| 417 | A Comparison of Lithium and T 3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report | 8.8 | 555 | Citations (PDF) |
| 418 | Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice | 8.8 | 3,611 | Citations (PDF) |
| 419 | Medication Augmentation after the Failure of SSRIs for Depression | 34.6 | 951 | Citations (PDF) |
| 420 | Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report | 8.8 | 5,061 | Citations (PDF) |
| 421 | Efficacy and Safety of Sildenafil in Men With Serotonergic Antidepressant-Associated Erectile Dysfunction | 1.8 | 75 | Citations (PDF) |
| 422 | Use of Treatment Algorithms for Depression | 1.8 | 15 | Citations (PDF) |
| 423 | A Cross-Sectional Study of the Prevalence of Cognitive and Physical Symptoms During Long-Term Antidepressant Treatment | 1.8 | 201 | Citations (PDF) |
| 424 | Commentary | 0.6 | 12 | Citations (PDF) |
| 425 | The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine | 2.7 | 84 | Citations (PDF) |
| 426 | A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder | 1.7 | 119 | Citations (PDF) |
| 427 | Empirical Testing of Two Models for Staging Antidepressant Treatment Resistance | 1.7 | 101 | Citations (PDF) |
| 428 | An Open-label Study of Duloxetine for the Treatment of Major Depressive Disorder | 1.7 | 24 | Citations (PDF) |
| 429 | Cardiovascular Risk Factors May Moderate Pharmacological Treatment Effects in Major Depressive Disorder | 2.2 | 57 | Citations (PDF) |
| 430 | Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features | 4.5 | 218 | Citations (PDF) |
| 431 | Immediate Switching of Antidepressant Therapy: Results from a Clinical Trial of Duloxetine | 1.4 | 19 | Citations (PDF) |
| 432 | The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder | 1.1 | 2 | Citations (PDF) |
| 433 | Relationships between major depressive disorder and comorbid anxiety and personality disorders | 4.0 | 32 | Citations (PDF) |
| 434 | Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses | 1.3 | 29 | Citations (PDF) |
| 435 | PSYCHOSOCIAL FACTORS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: Depression and Renal Disease | 1.1 | 41 | Citations (PDF) |
| 436 | A Multicenter, Placebo-Controlled Study of Modafinil Augmentation in Partial Responders to Selective Serotonin Reuptake Inhibitors With Persistent Fatigue and Sleepiness | 1.8 | 172 | Citations (PDF) |
| 437 | 15 Years of Clinical Experience With Bupropion HCl | 0.6 | 232 | Citations (PDF) |
| 438 | Ventromedial Prefrontal Cortex and Amygdala Dysfunction During an AngerInduction Positron Emission Tomography Study in Patients With Major DepressiveDisorder With Anger Attacks | 12.6 | 151 | Citations (PDF) |
| 439 | Tolerability Issues During Long-Term Treatment with Antidepressants | 1.4 | 139 | Citations (PDF) |
| 440 | Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D) | 2.9 | 7 | Citations (PDF) |
| 441 | Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines | 2.9 | 25 | Citations (PDF) |
| 442 | The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder | 4.5 | 82 | Citations (PDF) |
| 443 | Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design | 2.8 | 987 | Citations (PDF) |
| 444 | Quality of life assessments in major depressive disorder: a review of the literature | 2.6 | 280 | Citations (PDF) |
| 445 | Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D | 2.6 | 118 | Citations (PDF) |
| 446 | Impact of medical comorbid disease on antidepressant treatment of major depressive disorder | 5.3 | 62 | Citations (PDF) |
| 447 | Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses | 1.0 | 127 | Citations (PDF) |
| 448 | Factors that differentiate early vs. later onset of major depression disorder | 3.1 | 135 | Citations (PDF) |
| 449 | Effect of Medical Comorbidity on Response to Fluoxetine Augmentation or Dose Increase in Outpatients With Treatment-Resistant Depression | 2.6 | 28 | Citations (PDF) |
| 450 | Comorbid Medical Illness and Relapse of Major Depressive Disorder in the Continuation Phase of Treatment | 2.6 | 51 | Citations (PDF) |
| 451 | Serum Cholesterol in the Continuation Phase of Pharmacotherapy With Fluoxetine in Remitted Major Depressive Disorder | 1.7 | 10 | Citations (PDF) |
| 452 | The Effect of Duloxetine on Painful Physical Symptoms in Depressed Patients | 1.8 | 184 | Citations (PDF) |
| 453 | S-adenosyl-methionine in depression: A comprehensive review of the literature | 5.3 | 91 | Citations (PDF) |
| 454 | Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) study | 2.1 | 476 | Citations (PDF) |
| 455 | Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD) | 5.4 | 513 | Citations (PDF) |
| 456 | Diagnosis and definition of treatment-resistant depression | 5.4 | 1,255 | Citations (PDF) |
| 457 | Somatic symptoms in treatment-resistant depression | 3.1 | 50 | Citations (PDF) |
| 458 | Axis III disorders in treatment-resistant major depressive disorder | 3.1 | 26 | Citations (PDF) |
| 459 | Treatment of Antidepressant-Associated Sexual Dysfunction With Sildenafil | 16.6 | 190 | Citations (PDF) |
| 460 | HOPELESSNESS AND SUICIDAL IDEATION IN OUTPATIENTS WITH TREATMENT-RESISTANT DEPRESSION: PREVALENCE AND IMPACT ON TREATMENT OUTCOME | 1.0 | 57 | Citations (PDF) |
| 461 | The Impact of Medical Comorbidity on Acute Treatment in Major Depressive Disorder | 8.8 | 117 | Citations (PDF) |
| 462 | A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed | 1.2 | 5 | Citations (PDF) |
| 463 | Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine | 1.7 | 29 | Citations (PDF) |
| 464 | Title is missing! | 1.4 | 16 | Citations (PDF) |
| 465 | Fluoxetine treatment of depressed patients with comorbid anxiety disorders | 4.8 | 20 | Citations (PDF) |
| 466 | Effects of Adding Cognitive Therapy to Fluoxetine Dose Increase on Risk of Relapse and Residual Depressive Symptoms in Continuation Treatment of Major Depressive Disorder | 1.7 | 64 | Citations (PDF) |
| 467 | Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine | 1.7 | 120 | Citations (PDF) |
| 468 | Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia | 1.7 | 83 | Citations (PDF) |
| 469 | Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence,,, | 4.7 | 234 | Citations (PDF) |
| 470 | Depression and public health | 2.1 | 473 | Citations (PDF) |
| 471 | Elevated Cholesterol Levels Associated With Nonresponse to Fluoxetine Treatment in Major Depressive Disorder | 2.6 | 71 | Citations (PDF) |
| 472 | A survey of prescribing practices in the treatment of depression | 3.8 | 65 | Citations (PDF) |
| 473 | An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding | 1.8 | 37 | Citations (PDF) |
| 474 | Title is missing! | 1.4 | 44 | Citations (PDF) |
| 475 | Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence,,, | 4.7 | 86 | Citations (PDF) |
| 476 | Somatic Symptoms, Depression, and Antidepressant Treatment | 1.8 | 80 | Citations (PDF) |
| 477 | Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression | 4.5 | 111 | Citations (PDF) |
| 478 | Fenfluramine challenge in unipolar depression with and without anger attacks | 3.1 | 79 | Citations (PDF) |
| 479 | Major Depressive Disorder | 11.0 | 549 | Citations (PDF) |
| 480 | Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks | 4.5 | 31 | Citations (PDF) |
| 481 | Strategies for Augmentation of SSRI Treatment: A Survey of an Academic Psychopharmacology Practice | 1.9 | 13 | Citations (PDF) |
| 482 | Anger attacks in depression | 4.0 | 51 | Citations (PDF) |
| 483 | A Cross-Sectional Study of Private Psychiatric Practices under a Single-Payer Health Care System | 2.7 | 4 | Citations (PDF) |
| 484 | Are Dependency and Self-Criticism Risk Factors for Major Depressive Disorder? | 2.7 | 7 | Citations (PDF) |
| 485 | Major depressive subtypes and treatment response | 5.4 | 241 | Citations (PDF) |
| 486 | DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION | 2.1 | 698 | Citations (PDF) |
| 487 | Consumption of Alcohol, Nicotine, and Caffeine Among Depressed Outpatients | 2.6 | 73 | Citations (PDF) |
| 488 | Hostility changes following antidepressant treatment: Relationship to stress and negative thinking | 2.9 | 27 | Citations (PDF) |
| 489 | Continuation and Maintenance Treatments of Major Depressive Disorder | 0.3 | 41 | Citations (PDF) |
| 490 | An Open Trial of Methyltetrahydrofolate in Elderly Depressed Patients | 1.4 | 65 | Citations (PDF) |
| 491 | Prolactin and stress | 0.6 | 16 | Citations (PDF) |
| 492 | Nutrition and Depression: The Role of Folate | 5.6 | 156 | Citations (PDF) |
| 493 | Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning | 2.7 | 17 | Citations (PDF) |
| 494 | Similar Changes in Cognitions following Cognitive-Behavioral Therapy or Escitalopram for Major Depressive Disorder: Implications for Mechanisms of Change | 1.4 | 2 | Citations (PDF) |
| 495 | Nsi-189 Phosphate, A Novel Neurogenic Compound, Selectively Benefits Moderately Depressed Patients: A Post-Hoc Analysis of A Phase 2 Study of Major Depressive Disorder | 1.4 | 0 | Citations (PDF) |
| 496 | College Students with Depressive Symptoms with and without Fatigue: Differences in Functioning, Suicidality, Anxiety, and Depressive Severity | 1.4 | 0 | Citations (PDF) |
| 497 | Rising Placebo Response Rates Threaten the Validity of Antipsychotic Meta-Analyses | 1.4 | 1 | Citations (PDF) |
| 498 | Further Evidence for the Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) | 1.4 | 1 | Citations (PDF) |
| 499 | What is the Overlap between Subjective and Objective Cognitive Impairments in Mdd? | 1.4 | 3 | Citations (PDF) |
| 500 | Factors that Distinguish College Students with Depressive Symptoms with and without Suicidal Thoughts | 1.4 | 1 | Citations (PDF) |
| 501 | Estimating Causal Treatment Effects in the Sequential Parallel Comparison Design (SPCD) | 1.7 | 0 | Citations (PDF) |
| 502 | Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial | 8.8 | 2 | Citations (PDF) |
